The c-x-c chemokine receptor 4 (cxcr4) antagonists global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size -
The C-X-C
chemokine receptor 4 (CXCR4) antagonist market size has grown strongly
in recent years. It will grow from $1.49 billion in 2023 to $1.62
billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The
growth in the historic period can be attributed to increasing
transparency in clinical trial data, patient-centric healthcare
policies, rising prevalence of chemotherapy resistance, policies
emphasizing patient-centered care and access, and increasing preference
for targeted therapies.
The C-X-C chemokine receptor 4 (CXCR4) antagonist market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to expanding applications in HIV or AIDS, rising demand for stem cell mobilization, potential in autoimmune diseases, growth in biobanking initiatives, and integration of artificial intelligence (AI) in drug discovery. Major trends in the forecast period include increasing focus on orphan drug development, development of combination therapies, adoption of precision oncology approaches, expanding clinical trials for novel therapies, and advancements in drug delivery technologies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/c-x-c-chemokine-receptor-4-cxcr4-antagonists-global-market-report
Scope Of C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
Market Drivers -
The
increase in the prevalence of human immunodeficiency virus (HIV) is
expected to propel the growth of the spasmodic dysphonia treatment
market going forward. Human immunodeficiency virus (HIV) is a virus that
targets and weakens the immune system by attacking CD4 (T) cells,
potentially leading to AIDS if left untreated. HIV prevalence is rising
due to low awareness, limited healthcare access, higher transmission
rates, and inadequate prevention in some areas. CXCR4 antagonists block
the CXCR4 receptor, stopping HIV from accessing and infecting immune
cells, which aids in controlling the virus and enhancing the immune
response. For instance, according to Joint United Nations Programme on
HIV/AIDS (UNAIDS), in 2022, there were 39 million [33.1 million-45.7
million] HIV-positive people worldwide, with 1.3 million [1 million-1.7
million] people newly infected with HIV in 2022. Therefore, the increase
in the prevalence of human immunodeficiency virus (HIV) is driving the
growth of the CXCR4 antagonist market.
Market Trends -
Major
companies operating in the CXCR4 antagonist market are focusing on
developing bioequivalents to enhance treatment options and improve
patient outcomes in various diseases. Bioequivalent refers to
pharmaceutical products with similar bioavailability when compared under
similar conditions. For instance, in May 2024, Gland Pharma, an
India-based generic injectable manufacturing company, received approval
from the United States Food and Drug Administration (US FDA) for
Plerixafor Injection. The approved product is bioequivalent and
therapeutically equivalent to the reference listed drug (RLD), MOZOBIL
(plerixafor) injection of Genzyme Corporation. Plerixafor is a CXCR4
antagonist that, when used with granulocyte-colony stimulating factor,
helps to mobilize hematopoietic stem cells into the peripheral blood for
collection and autologous transplantation in patients with
non-Hodgkin's lymphoma and multiple myeloma.
The C-X-C chemokine receptor 4 (CXCR4) antagonists market covered in this report is segmented –
1) By Type: BL-8040, GMI-1359, Plerixafor (AMD3100), Balixafortide (POL6326), USL311, Burixafor (GPC-100), Other Types
2) By Route Of Administration: Oral, Injectable
3) By Product Pipeline: Approved, Clinical Trials, Pre-Clinical
4)
By Application: Cancer, Human Immunodeficiency Virus (HIV), Chronic
Inflammatory Disease, Stem Cell Mobilization, Immune And Autoimmune
Diseases
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Get an inside scoop of the c-x-c chemokine receptor 4 (cxcr4) antagonists market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18329&type=smp
Regional Insights -
North
America was the largest region in the C-X-C chemokine receptor type 4
antagonists market in 2023. The regions covered in the C-X-C chemokine
receptor 4 (CXCR4) antagonists market report are Asia-Pacific, Western
Europe, Eastern Europe, North America, South America, Middle East,
Africa.
Key Companies -
Major companies operating in the C-X-C
chemokine receptor 4 (CXCR4) antagonists market are Pfizer Inc.,
F-Hoffmann La Roche Ltd., Sanofi, Bristol-Myers Squibb Company,
AstraZeneca plc, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc.,
Takeda Chemical Industries Ltd., Kyowa Kirin Co. Ltd., BioLegend Inc.,
Kura Oncology Inc., CUSABIO TECHNOLOGY LLC, Cayman Chemical, X4
Pharmaceuticals Inc., BioLineRx Ltd., Spexis Ltd., Biokine Therapeutics
Ltd., GlycoMimetics, AnorMED Inc., CohBar Inc.
Table of Contents
1. Executive Summary
2. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Report Structure
3. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Trends And Strategies
4. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market – Macro Economic Scenario
5. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Size And Growth
…..
27. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment